[ad_1] Fundamental Analysis of Yes Bank: The second half of the calendar year 2022 was about banking PSUs giving multi-bagger returns to their shareholders. The rally was led by improvements in asset quality and record growth in advances. But there is another bank, although not the government, that has come out of recovery. The infamous … Read more
[ad_1] From MarketWatch Retirement: New Alzheimer’s drug shows some promise, but has big price tag. Lecanemab, which will be sold under the brand name Leqembi, will be priced at $26,500 per year. Leqembi has received a slightly warmer reception from the medical community than predecessor drug Aduhelm. What catch-up contribution? Congressional snafu leaves older retirement … Read more
[ad_1] Fundamental Analysis of Axis Bank: Banks occupy a substantial portion of the overall stock market and they find their way into the portfolios of many investors. This can be either through mutual funds or by directly investing in stocks. However, analyzing banking stocks for the purpose of investment is slightly different from analyzing stocks … Read more
